-----Original Message-----
From: Meir Weiss [mailto:[log in to unmask]]
Sent: Friday, July 08, 2005 14:24
To: [log in to unmask]
Subject: Israeli "know how" again b"h Emailing: Using the secrets of the
brain to promote scientific cooperation



The message is ready to be sent with the following file or link
attachments:

Shortcut to:
http://www.israel21c.com/bin/en.jsp?enDispWho=Articles%5El1032&enPage=Bl
ankPage&enDisplay=view&enDispWhat=object&enVersion=0&enZone=Health&

 HEALTH

Using the secrets of the brain to promote scientific cooperation
By David Brinn   July 03, 2005

There wasn't any one particular reason why some of the world's most
respected brain researchers gathered last week in a Jerusalem conference
center - there were lots of them!

According to Rutgers University Professor Mark Gluck - who, along with
world renown Hebrew University Professor Haggai Bergman, organized the
two day conference focusing on interdisciplinary approaches to
understanding Parkinson's disease - scientific, social and political
motives were among those behind the gathering.

"Scientifically, we brought together people from all over the world -
from the US, Europe and Israel - who are working on various aspects of
Parkinson's disease research and on addiction - the two share common
neuropathways," Gluck told ISRAEL21c during a lunch break at the
Mishkenot Sha'anim Conference Center in the Yemin Moshe neighborhood of
Jerusalem. "Different researchers in different countries are working on
the problems from various perspectives - like computer modeling.

"There's a specific scientific reason for holding the conference in
Israel - it's a world leader in the life sciences and information
technology - and the conference is a confluence of these two.
Particularly, we decided to hold the conference at Hebrew University
because it's a leading center in this field and has a center of
neurocomputation.

"My co-director - Prof Bergman - invented deep brain stimulation for
Parkinson's patients - a process that stimulates parts of the brain in
order to control motor tremors. So Israel's a natural place to hold the
conference."

Parkinson's is a progressive disease of the nervous system that affects
an estimated 1.2 million people in the United States and Canada.
Symptoms include tremors, body rigidity and problems in movement. Former
boxing champion Muhammad Ali, actor Michael J. Fox and former Attorney
General Janet Reno are among prominent victims of Parkinson's.

Bergman, working in the late 1980s with a Parkinson's monkey model,
discovered a group of cells located deep in the brain called the
sub-thalamic nucleus. When Parkinson's was present, he discovered, these
cells were overactive.

The question he strove to answer was: was the Parkinson's disease
causing the cells to be overactive, or was the overactivity causing
Parkinson's? To find out, Bergman injected a chemical into the brain to
kill the cells, and he discovered that the Parkinson's symptoms abated.

His research was published in 1990, and created the basic methodology
for a group of neurosurgeons in Grenoble, France, in 1993, to first
implant an electrode deep inside the brain of a human patient with
Parkinson's disease. The electrode triggered an electric impulse which
provided deep brain stimulation, and 'switched off' the overactive
cells, dramatically decreasing the level Parkinson's-induced involuntary
movement.

Following the success of the operation in Europe, the next centers to
attempt this operation were in the United States and Canada. In 2001,
when the procedure gained FDA approval, the number of hospitals in the
United States performing the operation mushroomed.

"In computational neuroscience, we're clearly one of the world leaders,"
Bergman told ISRAEL21c. "Our lab is coming out with new research all the
time. My group of 10 graduate students are having quite a good impact
and publishing in important journals. There aren't many American labs
that are doing as well."

Beyond science, the next reason Bergman and Gluck worked for three years
to make last week's conference - entitled 'Basal Ganglia, Dopamine, and
Learning: Integrating Computational and Clinical Perspectives ' - become
a reality, was the ever-present threat of a scientific boycott on Israel
by European colleagues.

"I found it really upsetting - an attack on my tribe twice over - fellow
Jews and fellow scientists," said Gluck. "And this was something that I
could do beyond being upset and annoyed. It's very rare to find an
international issue that somebody can actually have a voice in and
affect change. I thought that bringing leading scientists to Israel and
publicizing the fact was the best way to show that the most important
researchers are not being influenced by the boycott - and actually the
opposite was true: It was resulting in more and more collaborations."

Professor Jean Saint-Cyr of the University of Toronto - who lectured the
100 attendees about the connection between pathological gambling and
Parkinson's patient - called the boycott immoral.

"I'm fundamentally opposed to it, it's not as if scientists are
militants and adding their voices to any political problems in the area.
I think that science should be above all that. Being here is a signal
that we don't agree with the boycott ? we're voting with our feet," he
said.

If those weren't enough, another goal of the conference was to foster
three-way ties between the American and Israeli researchers and their
Palestinian counterparts. Al-Quds University in east Jerusalem was
originally one of the co-hosts of the conference along with Hebrew
University, but pressure on the Palestinian scientists caused them to
pare down their participation.

"I was in charge of reaching out to our Palestinian colleagues,"
explained Bergman. "I went to Al-Quds three or four times, and until two
weeks ago, everything was fine. Recently, however, they felt it was
beyond their ability to bring a group of scientists to the conference.
However, the dean of medical school and head of the neurology department
came for some sessions and met some of the people here.

"It's good that they were introduced to our colleagues from the US like
Mark.
Then the next time, the direct connection can be with them, and there
won't be as much pressure on them to deal directly with us. It was a
first step."

According to Gluck - co-director of the Rutgers Memory Disorders Project
- collaboration between Israeli and Palestinian scientists is desirable
for both sides, and he's glad to act as a mediator.

"I'm not naïve enough to believe that if scientists talk to each other
that it will lead directly to a resolution of the conflict. But it does
create an atmosphere of communications - in topics that are not
controversial. You don't start talking about the hardest things first,
but rather find areas of common interests," he said.

"For the Palestinians, Israel could be a fabulous neighbor. In terms of
health care advances, Israel is a leader, and regional cooperation would
enable that knowledge to filter to its neighbors."

The day following the conference, the 44-year-old Gluck was headed to
Al-Quds for meetings with colleagues there to discuss collaborative
research.

"We're trying to design some form of Parkinson's research that can be
done collaboratively with us, Hebrew University and Al Quds," he said,
explaining that at this stage, it would be easier for the Palestinian
scientists to collaborate with Israelis indirectly through American
involvement.

The energetic Gluck is not stopping there. The inaugural conference also
planted the seeds for a new Rutgers/Israel exchange program. The
Rutgers-Israel Biomedical Research and Education Exchange is expected to
grow into a comprehensive exchange program for study and collaborative
research - bringing Rutgers students and faculty to Israel and Israeli
scientists and students to Rutgers.

"The program will take US undergraduates interested in biomed research
and bring them to Israeli university labs. They'll grow professionally,
but in addition, they'll get the Israel experience, see the country for
themselves and get a new perspective," said Gluck.

"From what they read in the newspapers, most students know only about
the occasional violence and political struggles, but few are aware that
Israel is an amazing engine of scientific and medical innovation and
progress. By sending them over to do research in Israeli labs, I think
we can both increase US-Israeli links and collaboration in biomedical
research, as well as spread the good news and the strengths of Israel
like its amazing 21st century cutting edge research labs and the many
ways in which Israeli scientists and doctor are helping to improve
healthcare worldwide with their discoveries and innovations."

The University of Toronto's Saint-Cyr agrees that those interested in
neuroscience have much to learn from their Israeli colleagues.

"I've been working in neuroscience all my life and have met many Israeli
scientists, and they've always been top-notch. The educational
facilities here are as good as they get anyplace in the world. In
Canada, we've had many positive collaborations with Israeli scientists."






  © 2001-2004 ISRAEL21c.org. All rights reserved.


Note: To protect against computer viruses, e-mail programs may prevent
sending or receiving certain types of file attachments.  Check your
e-mail security settings to determine how attachments are handled.




begin 666 en.url
M6TEN=&5R;F5T4VAO<G1C=71=#0I54DP]:'1T<#HO+W=W=RYI<W)A96PR,6,N
M8V]M+V)I;B]E;BYJ<W _96Y$:7-P5VAO/4%R=&EC;&5S)35%;#$P,S(F96Y0
M86=E/4)L86YK4&%G929E;D1I<W!L87D]=FEE=R9E;D1I<W!7:&%T/6]B:F5C
M="9E;E9E<G-I;VX],"9E;EIO;F4]2&5A;'1H)@T*36]D:69I960]1C V1C5$
.1C1%.3@S0S4P,44R#0H`
`
end

begin 666 ATT00008.txt
$#0H-"@``
`
end